BCL2L1 and Thrombocytopenia: Navitoclax (ABT-263), a BH3-mimetic that inhibits BCL-2, BCL-XL, and BCL-W results in undesirable but manageable on-target thrombocytopenia due to the dependence of platelets on BCL-XL (Tse et al., 2008).